If you are visually impaired or blind, you can visit the PDF version by Pressing CONTROL + ALT + 4
<br /> DERMATOLOGY<br /> ISSN 2053-4213 Vol 7.1 • November 2019 • emjreviews.com<br /> + Review of<br /> EADV 2019<br /> Madrid, Spain<br /> FIGHT<br /> Abbreviated Prescribing Information for Kyntheum® 210mg solution for injection in pre-filled<br /> syringe Please refer to the full Summary of Product Characteristics (SmPC) approved in your<br /> country before prescribing. This medicinal product is subject to additional monitoring.<br /> This will allow quick identification of new safety information. Healthcare professionals<br /> are asked to report any suspected adverse reactions. Indication: Treatment of moderate<br /> to severe plaque psoriasis in adult patients who are candidates for systemic therapy.<br /> Active ingredient: Each pre-filled syringe contains 210mg brodalumab in 1.5ml solution.<br /> 1ml solution contains 140mg brodalumab. Dosage and administration: Posology: Adul<a title="EMJ Dermatology 7.1 2019 page 1" href="http://viewer.zmags.com/publication/4205a3a8?page=1"> DERMATOLOGY ISSN 2053-4213 </a> <a title="EMJ Dermatology 7.1 2019 page 2" href="http://viewer.zmags.com/publication/4205a3a8?page=2"> FIGHT Abbreviated Prescribing Information </a> <a title="EMJ Dermatology 7.1 2019 page 3" href="http://viewer.zmags.com/publication/4205a3a8?page=3"> FIGHT DIFFERENT Kyntheum® (brodalumab) is </a> <a title="EMJ Dermatology 7.1 2019 page 4" href="http://viewer.zmags.com/publication/4205a3a8?page=4"> Contents + EDITORIAL BOARD </a> <a title="EMJ Dermatology 7.1 2019 page 5" href="http://viewer.zmags.com/publication/4205a3a8?page=5"> “The diversity of dermatological inquiry is reflec</a> <a title="EMJ Dermatology 7.1 2019 page 6" href="http://viewer.zmags.com/publication/4205a3a8?page=6"> Editorial Board Editor-in-Chief Prof Lawrenc</a> <a title="EMJ Dermatology 7.1 2019 page 7" href="http://viewer.zmags.com/publication/4205a3a8?page=7"> Aims and Scope The European Medical Journal (EMJ)</a> <a title="EMJ Dermatology 7.1 2019 page 8" href="http://viewer.zmags.com/publication/4205a3a8?page=8"> EMJ Dermatol. Chief Executive Officer Spencer</a> <a title="EMJ Dermatology 7.1 2019 page 9" href="http://viewer.zmags.com/publication/4205a3a8?page=9"> Welcome To all our friends and collaborators</a> <a title="EMJ Dermatology 7.1 2019 page 10" href="http://viewer.zmags.com/publication/4205a3a8?page=10"> Durable efficacy FOR HER skin and beyond1,2 </a> <a title="EMJ Dermatology 7.1 2019 page 11" href="http://viewer.zmags.com/publication/4205a3a8?page=11"> Foreword Dear colleagues, Welcome to the latest e</a> <a title="EMJ Dermatology 7.1 2019 page 12" href="http://viewer.zmags.com/publication/4205a3a8?page=12"> </a> <a title="EMJ Dermatology 7.1 2019 page 13" href="http://viewer.zmags.com/publication/4205a3a8?page=13"> Congress Review Review of the 2019 European Ac</a> <a title="EMJ Dermatology 7.1 2019 page 14" href="http://viewer.zmags.com/publication/4205a3a8?page=14"> role in the risk of cancer spreading to other par</a> <a title="EMJ Dermatology 7.1 2019 page 15" href="http://viewer.zmags.com/publication/4205a3a8?page=15"> “They are dedicated to patient care and educa</a> <a title="EMJ Dermatology 7.1 2019 page 16" href="http://viewer.zmags.com/publication/4205a3a8?page=16"> Air Pollution Poses Hair Loss Risk POLLUTION c</a> <a title="EMJ Dermatology 7.1 2019 page 17" href="http://viewer.zmags.com/publication/4205a3a8?page=17"> Dietary Habits Could Be Key Acne Trigger ACNE</a> <a title="EMJ Dermatology 7.1 2019 page 18" href="http://viewer.zmags.com/publication/4205a3a8?page=18"> Families of Atopic Dermatitis Patients at Risk of</a> <a title="EMJ Dermatology 7.1 2019 page 19" href="http://viewer.zmags.com/publication/4205a3a8?page=19"> Mismanagement and High Levels of Anxiety Repor</a> <a title="EMJ Dermatology 7.1 2019 page 20" href="http://viewer.zmags.com/publication/4205a3a8?page=20"> Severity of Psoriasis Related to the Severity o</a> <a title="EMJ Dermatology 7.1 2019 page 21" href="http://viewer.zmags.com/publication/4205a3a8?page=21"> Malignant Melanoma Above the Neck Has Higher </a> <a title="EMJ Dermatology 7.1 2019 page 22" href="http://viewer.zmags.com/publication/4205a3a8?page=22"> Identification of The Most Influential Exposome </a> <a title="EMJ Dermatology 7.1 2019 page 23" href="http://viewer.zmags.com/publication/4205a3a8?page=23"> ® The 3D imaging solution for FACE, BREAST, and </a> <a title="EMJ Dermatology 7.1 2019 page 24" href="http://viewer.zmags.com/publication/4205a3a8?page=24"> Psoriasis and Atopic Dermatitis: Addressing </a> <a title="EMJ Dermatology 7.1 2019 page 25" href="http://viewer.zmags.com/publication/4205a3a8?page=25"> Meeting Summary Psoriasis and atopic dermatitis (</a> <a title="EMJ Dermatology 7.1 2019 page 26" href="http://viewer.zmags.com/publication/4205a3a8?page=26"> volar skin psoriasis may appear virtually identic</a> <a title="EMJ Dermatology 7.1 2019 page 27" href="http://viewer.zmags.com/publication/4205a3a8?page=27"> Antibodies targeting </a> <a title="EMJ Dermatology 7.1 2019 page 28" href="http://viewer.zmags.com/publication/4205a3a8?page=28"> Long-term PASI response was assessed using observ</a> <a title="EMJ Dermatology 7.1 2019 page 29" href="http://viewer.zmags.com/publication/4205a3a8?page=29"> incorporated: efficacy, safety, tolerability, </a> <a title="EMJ Dermatology 7.1 2019 page 30" href="http://viewer.zmags.com/publication/4205a3a8?page=30"> Positive Skin feedback alarmins </a> <a title="EMJ Dermatology 7.1 2019 page 31" href="http://viewer.zmags.com/publication/4205a3a8?page=31"> placebo-controlled Phase IIb study, tralokinumab </a> <a title="EMJ Dermatology 7.1 2019 page 32" href="http://viewer.zmags.com/publication/4205a3a8?page=32"> 32. Gordon KB et al. Phase 3 trials of i</a> <a title="EMJ Dermatology 7.1 2019 page 33" href="http://viewer.zmags.com/publication/4205a3a8?page=33"> Interact with us on social media. </a> <a title="EMJ Dermatology 7.1 2019 page 34" href="http://viewer.zmags.com/publication/4205a3a8?page=34"> Considering Tomorrow in Today’s Treatment Choice </a> <a title="EMJ Dermatology 7.1 2019 page 35" href="http://viewer.zmags.com/publication/4205a3a8?page=35"> Disclaimer: Certolizumab pegol </a> <a title="EMJ Dermatology 7.1 2019 page 36" href="http://viewer.zmags.com/publication/4205a3a8?page=36"> of CZP. Aligned with the unique Fc-free structure</a> <a title="EMJ Dermatology 7.1 2019 page 37" href="http://viewer.zmags.com/publication/4205a3a8?page=37"> 27%), more women had DLQI scores >10 (38% agent</a> <a title="EMJ Dermatology 7.1 2019 page 38" href="http://viewer.zmags.com/publication/4205a3a8?page=38"> Achieving Long-term Impact in Patients L</a> <a title="EMJ Dermatology 7.1 2019 page 39" href="http://viewer.zmags.com/publication/4205a3a8?page=39"> were identified during long-term treatment when </a> <a title="EMJ Dermatology 7.1 2019 page 40" href="http://viewer.zmags.com/publication/4205a3a8?page=40"> decreased with dose reduction to 200 mg Q2W, sugg</a> <a title="EMJ Dermatology 7.1 2019 page 41" href="http://viewer.zmags.com/publication/4205a3a8?page=41"> Plaque psoriasis impacts pregnancy and its o</a> <a title="EMJ Dermatology 7.1 2019 page 42" href="http://viewer.zmags.com/publication/4205a3a8?page=42"> clinical trial and registry data have been analys</a> <a title="EMJ Dermatology 7.1 2019 page 43" href="http://viewer.zmags.com/publication/4205a3a8?page=43"> 26. Murase JE et al. Hormonal effect on </a> <a title="EMJ Dermatology 7.1 2019 page 44" href="http://viewer.zmags.com/publication/4205a3a8?page=44"> Epithelial Barrier Dysfunction in Type 2 </a> <a title="EMJ Dermatology 7.1 2019 page 45" href="http://viewer.zmags.com/publication/4205a3a8?page=45"> epithelial barrier dysfunction, and inflammation c</a> <a title="EMJ Dermatology 7.1 2019 page 46" href="http://viewer.zmags.com/publication/4205a3a8?page=46"> release of mast-cell granules recruits leukocytes</a> <a title="EMJ Dermatology 7.1 2019 page 47" href="http://viewer.zmags.com/publication/4205a3a8?page=47"> AD histology is characterised by marked</a> <a title="EMJ Dermatology 7.1 2019 page 48" href="http://viewer.zmags.com/publication/4205a3a8?page=48"> airway hyper-responsiveness, airw</a> <a title="EMJ Dermatology 7.1 2019 page 49" href="http://viewer.zmags.com/publication/4205a3a8?page=49"> Knowledge Gaps in Type 2 Inflammatory Diseases (</a> <a title="EMJ Dermatology 7.1 2019 page 50" href="http://viewer.zmags.com/publication/4205a3a8?page=50"> References 1. Gazzinelli-Guimaraes PH, Nutma</a> <a title="EMJ Dermatology 7.1 2019 page 51" href="http://viewer.zmags.com/publication/4205a3a8?page=51"> corneum lipids in human skin 54.</a> <a title="EMJ Dermatology 7.1 2019 page 52" href="http://viewer.zmags.com/publication/4205a3a8?page=52"> Rosacea: The Patient Experience is Now 'CLEAR' T</a> <a title="EMJ Dermatology 7.1 2019 page 53" href="http://viewer.zmags.com/publication/4205a3a8?page=53"> Rosacea: The Patient Experience </a> <a title="EMJ Dermatology 7.1 2019 page 54" href="http://viewer.zmags.com/publication/4205a3a8?page=54"> 'Almost clear' (IGA 1) 'Clear' (IGA 0) A </a> <a title="EMJ Dermatology 7.1 2019 page 55" href="http://viewer.zmags.com/publication/4205a3a8?page=55"> In addition, achieving ‘clear’ can reduce t</a> <a title="EMJ Dermatology 7.1 2019 page 56" href="http://viewer.zmags.com/publication/4205a3a8?page=56"> MILD MOD SPF General skincare α-Adrenergics* Az</a> <a title="EMJ Dermatology 7.1 2019 page 57" href="http://viewer.zmags.com/publication/4205a3a8?page=57"> A Transient erythema (flushing) Ocular </a> <a title="EMJ Dermatology 7.1 2019 page 58" href="http://viewer.zmags.com/publication/4205a3a8?page=58"> At this point the patient felt hopeless about her</a> <a title="EMJ Dermatology 7.1 2019 page 59" href="http://viewer.zmags.com/publication/4205a3a8?page=59"> References 1. Wilkin J et al. Standard class</a> <a title="EMJ Dermatology 7.1 2019 page 60" href="http://viewer.zmags.com/publication/4205a3a8?page=60"> Abstract Reviews These abstract summaries </a> <a title="EMJ Dermatology 7.1 2019 page 61" href="http://viewer.zmags.com/publication/4205a3a8?page=61"> the information given to them regarding the</a> <a title="EMJ Dermatology 7.1 2019 page 62" href="http://viewer.zmags.com/publication/4205a3a8?page=62"> Table 1: Alternative therapies reported and reaso</a> <a title="EMJ Dermatology 7.1 2019 page 63" href="http://viewer.zmags.com/publication/4205a3a8?page=63"> There is, to date, little legislation regarding u</a> <a title="EMJ Dermatology 7.1 2019 page 64" href="http://viewer.zmags.com/publication/4205a3a8?page=64"> Figure 1: Erythematous bands on the back of hands</a> <a title="EMJ Dermatology 7.1 2019 page 65" href="http://viewer.zmags.com/publication/4205a3a8?page=65"> References 1. Winter L, “Paraneoplastic synd</a> <a title="EMJ Dermatology 7.1 2019 page 66" href="http://viewer.zmags.com/publication/4205a3a8?page=66"> A B Figure 1: A)</a> <a title="EMJ Dermatology 7.1 2019 page 67" href="http://viewer.zmags.com/publication/4205a3a8?page=67"> Analysis of Methods of the Demodex Mites Diagnos</a> <a title="EMJ Dermatology 7.1 2019 page 68" href="http://viewer.zmags.com/publication/4205a3a8?page=68"> quantification of demodex mites by confocal laser </a> <a title="EMJ Dermatology 7.1 2019 page 69" href="http://viewer.zmags.com/publication/4205a3a8?page=69"> Table 1: Quantitative indexes score. Itch-VAS T</a> <a title="EMJ Dermatology 7.1 2019 page 70" href="http://viewer.zmags.com/publication/4205a3a8?page=70"> Cutaneous Adverse Effects Induced by Nivolumab Au</a> <a title="EMJ Dermatology 7.1 2019 page 71" href="http://viewer.zmags.com/publication/4205a3a8?page=71"> References 1. Abdel-Wahab N et al. Adverse e</a> <a title="EMJ Dermatology 7.1 2019 page 72" href="http://viewer.zmags.com/publication/4205a3a8?page=72"> Erythema Multiforme: A Clinical Study of Thi</a> <a title="EMJ Dermatology 7.1 2019 page 73" href="http://viewer.zmags.com/publication/4205a3a8?page=73"> Combined Treatment of Acneiform Rash In</a> <a title="EMJ Dermatology 7.1 2019 page 74" href="http://viewer.zmags.com/publication/4205a3a8?page=74"> 3. Segaert S, Van Cutsem E. Clinical signs, pa</a> <a title="EMJ Dermatology 7.1 2019 page 75" href="http://viewer.zmags.com/publication/4205a3a8?page=75"> Want a daily dose of healthcare straigh</a> <a title="EMJ Dermatology 7.1 2019 page 76" href="http://viewer.zmags.com/publication/4205a3a8?page=76"> IEndteitrovrieawl Bsoard Interviews Introducing </a> <a title="EMJ Dermatology 7.1 2019 page 77" href="http://viewer.zmags.com/publication/4205a3a8?page=77"> In my 20 years of practice, the most common </a> <a title="EMJ Dermatology 7.1 2019 page 78" href="http://viewer.zmags.com/publication/4205a3a8?page=78"> sections on cosmeceuticals, botulinum toxin,</a> <a title="EMJ Dermatology 7.1 2019 page 79" href="http://viewer.zmags.com/publication/4205a3a8?page=79"> Prof Alin Tatu. Medical and Pharmaceutical Resear</a> <a title="EMJ Dermatology 7.1 2019 page 80" href="http://viewer.zmags.com/publication/4205a3a8?page=80"> Q5 Do you think there are any areas o</a> <a title="EMJ Dermatology 7.1 2019 page 81" href="http://viewer.zmags.com/publication/4205a3a8?page=81"> Acne Therapy Across Time in the USA </a> <a title="EMJ Dermatology 7.1 2019 page 82" href="http://viewer.zmags.com/publication/4205a3a8?page=82"> TREATMENTS Over the last century, new treatment o</a> <a title="EMJ Dermatology 7.1 2019 page 83" href="http://viewer.zmags.com/publication/4205a3a8?page=83"> TETRACYCLINES Topical minocycline is a relatively</a> <a title="EMJ Dermatology 7.1 2019 page 84" href="http://viewer.zmags.com/publication/4205a3a8?page=84"> currently undergoing Phase II–III clinical trials</a> <a title="EMJ Dermatology 7.1 2019 page 85" href="http://viewer.zmags.com/publication/4205a3a8?page=85"> trials.9,39-41 Peck et al.39 performed a double-b</a> <a title="EMJ Dermatology 7.1 2019 page 86" href="http://viewer.zmags.com/publication/4205a3a8?page=86"> lesions (p<0.05).60 The 1,550 nm erbium glass fra</a> <a title="EMJ Dermatology 7.1 2019 page 87" href="http://viewer.zmags.com/publication/4205a3a8?page=87"> References 1. Bickers DR et al. The burden o</a> <a title="EMJ Dermatology 7.1 2019 page 88" href="http://viewer.zmags.com/publication/4205a3a8?page=88"> acne. A randomized double-blind study. J Am Acad </a> <a title="EMJ Dermatology 7.1 2019 page 89" href="http://viewer.zmags.com/publication/4205a3a8?page=89"> Treatment of Atopic Dermatitis Using JAK </a> <a title="EMJ Dermatology 7.1 2019 page 90" href="http://viewer.zmags.com/publication/4205a3a8?page=90"> INTRODUCTION Atopic dermatitis (AD) is one o</a> <a title="EMJ Dermatology 7.1 2019 page 91" href="http://viewer.zmags.com/publication/4205a3a8?page=91"> meaningful alternative for patients afflicted wit</a> <a title="EMJ Dermatology 7.1 2019 page 92" href="http://viewer.zmags.com/publication/4205a3a8?page=92"> Table 1 continued. Nakagawa H et al.,27 2018 JAK </a> <a title="EMJ Dermatology 7.1 2019 page 93" href="http://viewer.zmags.com/publication/4205a3a8?page=93"> Table 1 continued. Levy LL et al.,31 2015 Tof</a> <a title="EMJ Dermatology 7.1 2019 page 94" href="http://viewer.zmags.com/publication/4205a3a8?page=94"> Table 2: Search strategies. Search Strategies MED</a> <a title="EMJ Dermatology 7.1 2019 page 95" href="http://viewer.zmags.com/publication/4205a3a8?page=95"> Records identified through database searchi</a> <a title="EMJ Dermatology 7.1 2019 page 96" href="http://viewer.zmags.com/publication/4205a3a8?page=96"> safety, and pharmacokinetics of JTE-052, a novel </a> <a title="EMJ Dermatology 7.1 2019 page 97" href="http://viewer.zmags.com/publication/4205a3a8?page=97"> in the tofacitinib group compared to 22% for the </a> <a title="EMJ Dermatology 7.1 2019 page 98" href="http://viewer.zmags.com/publication/4205a3a8?page=98"> consequently supressing skin inflammation.54 JT</a> <a title="EMJ Dermatology 7.1 2019 page 99" href="http://viewer.zmags.com/publication/4205a3a8?page=99"> PLoS One. 2012;7(7):e39803. 4. Williams H et a</a> <a title="EMJ Dermatology 7.1 2019 page 100" href="http://viewer.zmags.com/publication/4205a3a8?page=100"> 87. 45. Wohlmann A et al. Signal transdu</a> <a title="EMJ Dermatology 7.1 2019 page 101" href="http://viewer.zmags.com/publication/4205a3a8?page=101"> Near Circumferential Invasive Proliferative Gel</a> <a title="EMJ Dermatology 7.1 2019 page 102" href="http://viewer.zmags.com/publication/4205a3a8?page=102"> 2. Typical topography: axillae, groins, perineal</a> <a title="EMJ Dermatology 7.1 2019 page 103" href="http://viewer.zmags.com/publication/4205a3a8?page=103"> A B Figure 2: A) lateral calf wound</a> <a title="EMJ Dermatology 7.1 2019 page 104" href="http://viewer.zmags.com/publication/4205a3a8?page=104"> During debridement, the ulcer was noted to be unu</a> <a title="EMJ Dermatology 7.1 2019 page 105" href="http://viewer.zmags.com/publication/4205a3a8?page=105"> this current case, the lesion was successfully tr</a> <a title="EMJ Dermatology 7.1 2019 page 106" href="http://viewer.zmags.com/publication/4205a3a8?page=106"> Serum Sickness-Like Reaction in Children: Review </a> <a title="EMJ Dermatology 7.1 2019 page 107" href="http://viewer.zmags.com/publication/4205a3a8?page=107"> be different from the classic SS, because SSLR is</a> <a title="EMJ Dermatology 7.1 2019 page 108" href="http://viewer.zmags.com/publication/4205a3a8?page=108"> A B Figure 1. A) Erythematous papules </a> <a title="EMJ Dermatology 7.1 2019 page 109" href="http://viewer.zmags.com/publication/4205a3a8?page=109"> CIC: circulating immune complexes; ESR: erythrocy</a> <a title="EMJ Dermatology 7.1 2019 page 110" href="http://viewer.zmags.com/publication/4205a3a8?page=110"> INVESTIGATIONS Currently, the diagnosis of SS</a> <a title="EMJ Dermatology 7.1 2019 page 111" href="http://viewer.zmags.com/publication/4205a3a8?page=111"> ankles bilaterally (hands and feet), but other jo</a> <a title="EMJ Dermatology 7.1 2019 page 112" href="http://viewer.zmags.com/publication/4205a3a8?page=112"> IL-23 Inhibitors for Moderate-to-Severe Plaque Ps</a> <a title="EMJ Dermatology 7.1 2019 page 113" href="http://viewer.zmags.com/publication/4205a3a8?page=113"> Table 1: Pivotal Phase III trials for guselkumab.</a> <a title="EMJ Dermatology 7.1 2019 page 114" href="http://viewer.zmags.com/publication/4205a3a8?page=114"> Standardised scoring systems used to evaluate the</a> <a title="EMJ Dermatology 7.1 2019 page 115" href="http://viewer.zmags.com/publication/4205a3a8?page=115"> Table 2: Pivotal Phase III trials for tildrakizum</a> <a title="EMJ Dermatology 7.1 2019 page 116" href="http://viewer.zmags.com/publication/4205a3a8?page=116"> adalimumab were also maintained at Week 24. At We</a> <a title="EMJ Dermatology 7.1 2019 page 117" href="http://viewer.zmags.com/publication/4205a3a8?page=117"> NAVIGATE was a Phase III randomised, double- blin</a> <a title="EMJ Dermatology 7.1 2019 page 118" href="http://viewer.zmags.com/publication/4205a3a8?page=118"> and EMA approval in September 2018 for the treatm</a> <a title="EMJ Dermatology 7.1 2019 page 119" href="http://viewer.zmags.com/publication/4205a3a8?page=119"> from the reSURFACE 1 and 2 trials for the rates o</a> <a title="EMJ Dermatology 7.1 2019 page 120" href="http://viewer.zmags.com/publication/4205a3a8?page=120"> Table 3: Pivotal Phase III trials for risankizuma</a> <a title="EMJ Dermatology 7.1 2019 page 121" href="http://viewer.zmags.com/publication/4205a3a8?page=121"> IMMvent randomised patients 1:1 to risankizumab 1</a> <a title="EMJ Dermatology 7.1 2019 page 122" href="http://viewer.zmags.com/publication/4205a3a8?page=122"> References 1. Koo J. Population-based </a> <a title="EMJ Dermatology 7.1 2019 page 123" href="http://viewer.zmags.com/publication/4205a3a8?page=123"> of two randomized Phase III clinical 41. t</a>